What Does FDA Deem A "Serious Adverse Event"? Matrixx Learns The Hard Way

A narrower interpretation of "serious adverse event" - compared with FDA's definition - is costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products - assuming FDA cannot be convinced to reverse its position